ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Proteomics International Laboratories Ltd (PK)

Proteomics International Laboratories Ltd (PK) (PIQLF)

0,26
0,00
(0,00%)
Geschlossen 07 Juni 10:00PM

Proteomics International Laboratories Ltd (PK) (PIQLF) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
0,26
( - )
Gebot
0,26
Fragen
0,26
Volumen
-
0,00 Tagesbereich 0,00
0,26 52-Wochen-Bereich 0,31
Marktkapitalisierung
Handelsende
0,26
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 412.666
Ausgegebene Aktien
165.183.999
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-2,02
Gewinn pro Aktie (EPS)
-0,07
Erlöse (LTM)
3,21M
Nettogewinn (LTM)
-9,66M

Über Proteomics International Laboratories Ltd (PK)

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s prod... Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
Perth, Australia
Gegründet
2026
Proteomics International Laboratories Ltd (PK) is listed in the Healthcare sector of the OTC Markets with ticker PIQLF. The last closing price for Proteomics International... (PK) was US$0,26. Over the last year, Proteomics International... (PK) shares have traded in a share price range of US$ 0,26 to US$ 0,31.

Proteomics International... (PK) currently has 165.183.999 shares in issue. The market capitalisation of Proteomics International... (PK) is US$42,95 million. Proteomics International... (PK) has a price to earnings ratio (PE ratio) of -2.02.

PIQLF Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
12000.260.260.2600CS
26000.260.260.2600CS
52-0.05-16.12903225810.310.310.26530.26CS
156-0.05-16.12903225810.310.310.2611820.30807692CS
260-0.05-16.12903225810.310.310.2611820.30807692CS

PIQLF - Frequently Asked Questions (FAQ)

What is the current Proteomics International Laboratories Ltd (PK) share price?
The current share price of Proteomics International Laboratories Ltd (PK) is US$ 0,26
How many Proteomics International Laboratories Ltd (PK) shares are in issue?
Proteomics International Laboratories Ltd (PK) has 165.183.999 shares in issue
What is the market cap of Proteomics International Laboratories Ltd (PK)?
The market capitalisation of Proteomics International Laboratories Ltd (PK) is USD 42,95M
What is the 1 year trading range for Proteomics International Laboratories Ltd (PK) share price?
Proteomics International Laboratories Ltd (PK) has traded in the range of US$ 0,26 to US$ 0,31 during the past year
What is the PE ratio of Proteomics International Laboratories Ltd (PK)?
The price to earnings ratio of Proteomics International Laboratories Ltd (PK) is -2,02
What is the cash to sales ratio of Proteomics International Laboratories Ltd (PK)?
The cash to sales ratio of Proteomics International Laboratories Ltd (PK) is 7,47
What is the registered address of Proteomics International Laboratories Ltd (PK)?
The registered address for Proteomics International Laboratories Ltd (PK) is QEII Medical Centre, Perth, Western Australia, 6009
What is the Proteomics International Laboratories Ltd (PK) website address?
The website address for Proteomics International Laboratories Ltd (PK) is www.proteomics.com.au
Which industry sector does Proteomics International Laboratories Ltd (PK) operate in?
Proteomics International Laboratories Ltd (PK) operates in the Biotechnology & Life Sciences sector

PIQLF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen